

# NYRx Brand Less Than Generic Program Update

---

## What Pharmacy Providers and Prescribers Need to Know

Effective **August 1, 2024**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Myrbetriq®** and **Victoza®** will be **ADDED** to the program.
- **Dexilant®, Lialda®,** and **Renvela® powder pack and tablets** will be **REMOVED** from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the least expensive alternative for the patient. Brand name drugs included in this program:

- Do not require “Dispense as Written” (DAW) or “Brand Medically Necessary” on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of “1”; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code “1” and “Brand Medically Necessary” on the prescription.

For a complete list, see [NYRx Brand Less Than Generic Drugs](#) on the next page.

## NYRx Brand Less Than Generic Drugs

List of Brand Name Drugs included in this program**		
Advair Diskus®	Farxiga®	Retin-A® cream
Advair HFA®	Glumetza®	Risperdal Consta®
Alphagan P® 0.15%	Istalol®	Ritalin LA®
Alphagan P® 0.1%	Kitabis® Pak	Spiriva® Handihaler®
Apriso®	Kombiglyze® XR	Symbicort®
Azopt™	<b>Myrbetriq®</b>	Tegretol® suspension
Bethkis®	Nascobal®	Tegretol® XR
Carbaglu®	Nexavar®	Trileptal® suspension
CellCept® suspension	NuvaRing®	Vascepa®
Combigan®	Onglyza®	Ventolin® HFA
Copaxone® 20 mg SQ	Oseni®	<b>Victoza®</b>
Daytrana®	Pentasa®	Votrient®
Depakote® Sprinkle	Pradaxa®	Vyvanse® capsules
Dymista®	Protonix® suspension	Xigduo® XR
EpiPen	Pylera®	Xopenex HFA®
EpiPen, Jr	Restasis®	Zegerid® Rx

\* This list is subject to change. For the most recent updates, see the [Brand Less Than Generic Program Updates](#).

\* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.